secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009840
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive Biotechnologies reports preliminary Q4/FY2025 revenue growth of 51%/55% YoY
--------------------------------------------------------------------------------

- Total revenue FY2025 ~$277M (+55% YoY); Q4 ~$72M (+51% YoY).
- MRD revenue FY2025 ~$212M (+46% YoY); excluding milestone revenue grew 45%.
- clonoSEQ test volume FY2025 ~105,600 tests (+39% YoY); Q4 ~30,000 tests (+43% YoY).
- Cash, cash equivalents and marketable securities ~$227M as of Dec 31, 2025.
- Company expects full FY2025 net loss to decrease vs 2024; complete results due Feb 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000119312526009840/0001193125-26-009840-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000119312526009840/d29941d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009840

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer